Compare ERC & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERC | CVRX |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.1M | 221.2M |
| IPO Year | N/A | 2021 |
| Metric | ERC | CVRX |
|---|---|---|
| Price | $9.37 | $7.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $13.17 |
| AVG Volume (30 Days) | 64.4K | ★ 160.7K |
| Earning Date | 01-01-0001 | 02-03-2026 |
| Dividend Yield | ★ 8.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | N/A | ★ $55,969,000.00 |
| Revenue This Year | N/A | $11.49 |
| Revenue Next Year | N/A | $16.26 |
| P/E Ratio | $12.92 | ★ N/A |
| Revenue Growth | N/A | ★ 18.44 |
| 52 Week Low | $8.51 | $4.30 |
| 52 Week High | $9.74 | $18.55 |
| Indicator | ERC | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.42 | 29.46 |
| Support Level | $9.25 | $7.14 |
| Resistance Level | $9.49 | $8.44 |
| Average True Range (ATR) | 0.07 | 0.54 |
| MACD | -0.00 | -0.10 |
| Stochastic Oscillator | 46.45 | 17.87 |
Allspring Multi-Sector Income Fund is a closed-end investment management company. The company's core business is to secure a high level of income for its investors consistent with limiting its overall exposure to domestic interest rate risk. It invests in U.S. dollar-denominated below investment-grade bonds, debentures, and other income obligations, including loans and preferred stocks, developed and emerging market debt securities, including obligations of foreign governments or governmental entities, foreign corporations, or supranational agencies denominated in various currencies, asset backed securities and investment grade corporate bonds.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.